Results 121 to 130 of about 96,938 (286)

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Anaplastic Wilms' tumor: clinical and pathologic studies.

, 1985
A review of almost 1,200 children participating in the first and second National Wilms' Tumor Study (NWTS-1 and -2) has demonstrated a number of significant differences in the clinical presentation and response to therapy of anaplastic and nonanaplastic
B Storer, P Norkool, V T Farewell, G J D'Angio, J F Bonadio, J B Beckwith   +5 more
core   +1 more source

Five‐Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient‐Initiated Nationwide Survey in Japan

Cancer Science, EarlyView.
This nationwide survey reveals that comprehensive multigene testing for advanced NSCLC has rapidly expanded in Japan, steadily increasing the use of targeted therapies for rare oncogenic drivers. Despite these diagnostic advancements, approximately 30% of patients consistently remain untested, highlighting a persistent clinical gap in real‐world ...
Satoshi Ikeda, Kazuo Hasegawa, Takayuki Takahama, Kenta Kachi, Akihiro Yanagisawa, Sachiko Kawakami, Masashi Yoshida, Miyuki Sakai, Sachiko Watanabe, Kazuhiko Nakagawa   +9 more
wiley   +1 more source

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source

Perioperative Durvalumab for Resectable NSCLC: Updated Outcomes for Japanese Patients in AEGEAN

Cancer Science, EarlyView.
In prespecified exploratory analyses of Japanese patients with resectable NSCLC enrolled in the AEGEAN trial, perioperative durvalumab plus neoadjuvant chemotherapy demonstrated clinically meaningful improvements in the primary endpoints of EFS and pCR versus neoadjuvant chemotherapy alone.
Tetsuya Mitsudomi, John V. Heymach, Yoshitsugu Horio, Fumihiro Tanaka, Hiroshi Tanaka, Shoichi Kuyama, Morihito Okada, Shinichi Toyooka, Yasutaka Watanabe, Martin Reck, David Harpole, Janis M. Taube, Yuka Olivo, Huiling Xiong, Tamer M. Fouad, Allen Chen, Hiroaki Akamatsu   +16 more
wiley   +1 more source

Ganglioglioma with anaplastic transformation [PDF]

Arquivos de Neuro-Psiquiatria, 2012
Fabiano Reis, Guilherme Henrique Alves Vieira, Ricardo Schwingel, Vinicius Trindade Gonçalves, Luciano de Souza Queiroz   +4 more
openaire   +3 more sources

Phase II Study of Cisplatin/Gemcitabine Plus Necitumumab for Squamous NSCLC After ICI‐Platinum Therapy (WJOG14120L)

Cancer Science, EarlyView.
WJOG14120L NESSIE evaluated cisplatin, gemcitabine, and necitumumab (CGN) as second‐line therapy after ICI‐based treatment in 46 patients with advanced squamous NSCLC. ORR was 26.1%, DCR 87.0%, and median PFS 4.4 months. Although the predefined ORR threshold was not met, CGN showed modest antitumor activity with manageable toxicity.
Hiroshige Yoshioka, Keita Mori, Nobuhisa Ishikawa, Hiroaki Kanemura, Koichi Azuma, Yukihiro Toi, Hiroshi Handa, Yosuke Tamura, Hiroaki Akamatsu, Haruko Daga, Masafumi Yamaguchi, Teppei Yamaguchi, Yuki Sato, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Takayasu Kurata   +15 more
wiley   +1 more source

A 67‐year‐old man with a spinal extramedullary mass

Brain Pathology, EarlyView.
Marcella Callea, Francesco Costa, Rosina Paterra, Valeria Barresi   +3 more
wiley   +1 more source

Anaplastic Thyroid Carcinoma [PDF]

Ear, Nose & Throat Journal, 2007
Troy, Hutchins, Paul, Friedlander, Enrique, Palacios   +2 more
openaire   +2 more sources

Anaplastic Thyroid Carcinoma, Version 2.2015

, 2015
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update.
Lori J. Wirth, Fouad Kandeel, David Byrd, Thomas N. Wang, Duh, Quan-Yang, Carl Hoh, Ehya, Hormoz, Karin G. Hoffmann, Callender, Glenda, Judith C. McCaffrey, Hunt, Jason P, Wirth, Lori J, Busaidy, Naifa Lamki, Wang, Thomas N, Dominick M. Lamonica, Quan-Yang Duh, William M. Lydiatt, Hoffmann, Karin G, Dickson, Paxton, Christopher D. Raeburn, Lydiatt, William M, Raeburn, Christopher D, Ball, Douglas W, Robert I. Haddad, Haddad, Robert I, McCaffrey, Judith C, Randall P. Scheri, Robert C. Smallridge, Scheri, Randall P, Kandeel, Fouad, Hughes, Miranda, Andrei Iagaru, Ringel, Matthew D, Paxton Dickson, John A. Ridge, Ridge, John A, Hormoz Ehya, Megan Haymart, Jason P. Hunt, Lee Parks, Matthew D. Ringel, Jeffrey F. Moley, Haymart, Megan, Glenda Callender, Byrd, David, Cord Sturgeon, Miranda Hughes, Kopp, Peter, Lamonica, Dominick M, Moley, Jeffrey F, Douglas W. Ball, Sturgeon, Cord, Iagaru, Andrei, Hoh, Carl, Shah, Jatin P, Smallridge, Robert C, Parks, Lee, Peter Kopp, Jatin P. Shah, Naifa Lamki Busaidy   +59 more
core   +1 more source